Effect of acid-suppressive therapy on Helicobacter pylori production of interleukin-8 in the gastric mucosa.
BACKGROUND
Recent studies have shown that acid-suppressive therapy increases the severity of Helicobacter pylori- associated gastritis in the corpus.


OBJECTIVE
To evaluate interleukin (IL)-8 production in the gastric corpus mucosa before and during acid-suppressive therapy in H pylori-infected patients.


METHODS
Ten patients with reflux esophagitis (five H pylori-positive and five H pylori-negative) were treated with omeprazole 20 mg. Serum gastrin concentrations, H pylori colonization density and mucosal IL-8 levels in the corpus were investigated at entry and two weeks after starting therapy. IL-8 levels were measured by ELISA. The organism density was determined, and scored according to area occupied by the bacterial colonies. The presence of H pylori was assessed by rapid urease testing and histological finding of gastric biopsy specimens.


RESULTS
In H pylori-positive patients, concentrations of IL-8 during therapy significantly exceeded those before therapy (36.2+/-6. 8 versus 18.3+/-3.8 pg/mg protein; P<0.05) without altering H pylori density. In H pylori-negative patients, IL-8 levels were similar before and during therapy (6.1+/-2.7 versus 6.3+/-3.0 pg/mg protein). Concentrations of gastrin during therapy were significantly higher than those before therapy in all patients.


CONCLUSIONS
The results suggest that acid suppression increases mucosal IL-8 levels in H pylori-infected patients with reflux esophagitis.
Yoshinaga
M
M
Fukuoka Teishin Hospital, Japan. m-yoshi@winter.try-net.or.jp
Ohtani
A
A
Tsuruta
S
S
Kato
T
T
Higashi
E
E
Yamada
Y
Y
Harada
N
N
Nawata
H
H
D000328:Adult; D000368:Aged; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004942:Esophagitis, Peptic / Q000382:microbiology*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology*; D016481:Helicobacter Infections / Q000378:metabolism*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D016209:Interleukin-8; D009853:Omeprazole